...zzaniga, professor of psychology at UC Santa Barba...f the Mind, has received the Humboldt Research Pri...nce. , "Professor Gazzaniga is a true pioneer in ...tal human questions about the relationship between...ng. "The Humboldt Research Prize is a prestigious ...
...g up in Brooklyn, NY, UC Riverside,s Jerome Schul...home to peer into a microscope to examine slides o... Over the years, that early interest in science ev... the intersection of biology and engineering tha...IChE ), in celebrating its centennial this year, h...
...study finds that genes significantly affect variat...asons why people vote and participate in the polit...al scientists James H. Fowler, Christopher T. Dawe...r (of University of Southern California), appears ...e Review , a journal of the American Political Sci...
Other Biology News:Neuroscientist Michael Gazzaniga awarded Humboldt Prize 2UC Riverside bioengineer receives high honor from chemical engineers 2UC Riverside bioengineer receives high honor from chemical engineers 3UC Riverside bioengineer receives high honor from chemical engineers 4Why do people vote? Genetic variation in political participation 2(Date:11/20/2009)... Dendreon Corporation (N...and Drug Administration (FDA) provided written ack...License Application (BLA) for PROVENGE® (sipu...igned a Prescription Drug User Fee Act (PDUFA) dat... Dendreon,s amended BLA. Dendreon is seeking lice...
(Date:11/20/2009)...TTLER TOLEDO recently announced that Dr. Dominique...Role of Process Analytical Technology (PAT) in Gre...ber 1, 2009. , (PRWEB) No... Analytical Technology (PAT) in Green Chemistry an...s Analytical Technology (PAT) case studies will be...
(Date:11/19/2009)...SDA, Md., Nov. 19 Spheri...iotechnology for diabetes therapy, and a provider ... food, supplement, biotechnology and pharmaceutica...sly reported $6.3 million registered direct placem... of its common stock and warrants to purchase up t...
(Date:11/19/2009)... /PRNewswire/ - Aegera Therapeutics Inc. announced...ized Phase 2B study of AEG35156, a targeted antise...ple oncology indications. ,, The study, entitle...-Linked Inhibitor of Apoptosis (XIAP) Antisense AE...ine and Idarubicin in AML Following Failure of a S...
Breaking Biology Technology:Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2...., March 31 ImaRx Therapeutics, Inc., a,biopharma...erapies for,vascular disorders, today provided a c... year 2007 financial results., 2007 Year in Revi...dy -- Received FDA approval to market urokinase ... strategic licensing agreement with Bracco Interna...
...erformance Meets Simplicity for Routine and Resear...O ALTO, Calif., March 31 Varian, Inc.,(NasdaqGS: ...IR (Fourier,Transform Infrared) spectrometers, mic...es a range of products for both routine analyses a...scopy provides a simple, fast analytical tool to i...
...lif., March 31 Immunosyn,Corporation (OTC Bulleti...ined exclusive worldwide marketing, sales and dist...has announced its results for the fiscal,year endi...r 31, 2007, the company incurred $647,000 in,gener...rest expense which,was funded from advances by aff...
Other Biology Technology:ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 2ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 3ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 4ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 5ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 6ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 7ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 8ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 9ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 10New FT-IR Spectrometer Series from Varian, Inc. 2Immunosyn Corporation Announces 2007 Results, Files 10KSB 2Immunosyn Corporation Announces 2007 Results, Files 10KSB 3MUTAN SUPER EXPRESS KM 20 RXN from Takara Mirus Bio
...the 9, 10, 12, and 13 positions. It is intended fo...on of 13(S)-HODE by GC- or LC-mass spectrometry. 1...id with plant and mammalian lipoxygenases. It has ...to the endothelium at concentrations around 1 ...
... are recommended for protein expression from pTriE...tion has been selected based on rapid, vigorous ce...ved specifically with baculoviruses derived from t...-Plaque Sf9 Cells and BacVector Insect Cell Medium...
Adaptor BamH I-Sma I from Takara Mirus Bio
Biology Products: